Patents by Inventor Muneto Narita

Muneto Narita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRANSMUCOSAL DELIVERY SYSTEM FOR PHARMACEUTICAL ACTIVE INGREDIENT TO SUBMUCOSAL TISSUE OF BLADDER
    Publication number: 20220370630
    Abstract: As a system that enables effective delivery of a pharmaceutical active ingredient to a submucosal tissue of the bladder, a transmucosal delivery system including a conjugate of a hydrophobic compound containing the pharmaceutical active ingredient and chondroitin sulfate is provided.
    Type: Application
    Filed: October 2, 2020
    Publication date: November 24, 2022
    Applicant: SEIKAGAKU CORPORATION
    Inventors: Muneto NARITA, Kensuke ISHII, Akihito SHIMURA
  • Chondroitin sulfate derivative and agent for treating bladder diseases
    Patent number: 10953037
    Abstract: A compound includes a group derived from chondroitin sulfate, a group derived from a steroid, and a spacer. The group derived from the chondroitin sulfate and the group derived from the steroid are covalently bonded together via the spacer, and a spacer forming molecule of the spacer is ?-alanine or isoleucine. A covalent bond between the group derived from the steroid and the spacer is an ester bond, and a covalent bond between the group derived from the chondroitin sulfate and the spacer is an amide bond. The steroid is at least one selected from the group consisting of prednisolone, betamethasone, triamcinolone, triamcinolone acetonide, budesonide and fluticasone.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: March 23, 2021
    Assignee: SEIKAGAKU CORPORATION
    Inventors: Muneto Narita, Takahiro Hatanaka, Yuko Yoshida
  • CHONDROITIN SULFATE DERIVATIVE AND AGENT FOR TREATING BLADDER DISEASES
    Publication number: 20190282607
    Abstract: A compound includes a group derived from chondroitin sulfate, a group derived from a steroid, and a spacer. The group derived from the chondroitin sulfate and the group derived from the steroid are covalently bonded together via the spacer, and a spacer forming molecule of the spacer is ?-alanine or isoleucine. A covalent bond between the group derived from the steroid and the spacer is an ester bond, and a covalent bond between the group derived from the chondroitin sulfate and the spacer is an amide bond. The steroid is at least one selected from the group consisting of prednisolone, betamethasone, triamcinolone, triamcinolone acetonide, budesonide and fluticasone.
    Type: Application
    Filed: May 31, 2019
    Publication date: September 19, 2019
    Applicant: Seikagaku Corporation
    Inventors: Muneto Narita, Takahiro Hatanaka, Yuko Yoshida
  • Chondroitin sulfate derivative and agent for treating bladder diseases
    Patent number: 10350236
    Abstract: Provided is a compound in which a group derived from chondroitin sulfate and a group derived from a steroid are covalently bonded together via a spacer represented by general formula (I). In the formula, m represents an integer of 0 or 1. Here, if m=0, R1 represents a group selected from the group consisting of electron-donating groups and steric hindrance groups. If m=1, R1 represents a group selected from the group consisting of a hydrogen atom, electron-donating groups and steric hindrance groups.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: July 16, 2019
    Assignee: Seikagaku Corporation
    Inventors: Muneto Narita, Takahiro Hatanaka, Yuko Yoshida
  • CHONDROITIN SULFATE DERIVATIVE AND AGENT FOR TREATING BLADDER DISEASES
    Publication number: 20170354675
    Abstract: Provided is a compound in which a group derived from chondroitin sulfate and a group derived from a steroid are covalently bonded together via a spacer represented by general formula (I). In the formula, m represents an integer of 0 or 1. Here, if m=0, R1 represents a group selected from the group consisting of electron-donating groups and steric hindrance groups. If m=1, R1 represents a group selected from the group consisting of a hydrogen atom, electron-donating groups and steric hindrance groups.
    Type: Application
    Filed: January 8, 2016
    Publication date: December 14, 2017
    Applicant: Seikagaku Corporation
    Inventors: Muneto Narita, Takahiro Hatanaka, Yuko Yoshida